List of Excipients in Branded Drug TIGECYCLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	HYDROCHLORIC ACID
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	MALTOSE
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	SODIUM HYDROXIDE

Generic Drugs Containing TIGECYCLINE

Company	Ingredient	NDC	Excipient
Sandoz Inc	tigecycline	0781-3481	HYDROCHLORIC ACID
Sandoz Inc	tigecycline	0781-3481	LACTOSE MONOHYDRATE
Sandoz Inc	tigecycline	0781-3481	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TIGECYCLINE?

# Of NDCs	Excipient
4	HYDROCHLORIC ACID
4	LACTOSE MONOHYDRATE
4	SODIUM HYDROXIDE

Tigecycline Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Tigecycline is an injectable glycylcycline antibiotic with a commercial opportunity centered on delivery, stability, administration convenience, and differentiated hospital formulations rather than new active-ingredient claims. The reference product, Tygacil, is a sterile, preservative-free, lyophilized powder for intravenous infusion containing tigecycline, lactose monohydrate, hydrochloric acid, and sodium hydroxide for pH adjustment.[1]

The strongest product strategies are ready-to-use presentations, reduced reconstitution burden, improved in-use stability, lower preparation error risk, and packaging systems that support hospital pharmacy automation. Conventional generic powder-for-injection products face limited differentiation unless they improve workflow, compatibility, supply reliability, or total treatment cost.

What excipients are used in Tygacil tigecycline injection?

Tygacil is supplied as a 50 mg lyophilized powder in a single-dose vial. The labeled formulation contains:

Component	Function
Tigecycline	Active antibacterial ingredient
Lactose monohydrate	Bulking and cake-forming agent
Hydrochloric acid	pH adjustment
Sodium hydroxide	pH adjustment

The product is reconstituted with an approved intravenous diluent and then further diluted before infusion. The labeled diluents include 0.9% sodium chloride injection, 5% dextrose injection, and certain compatible solutions identified in the prescribing information.[1]

The formulation is designed for parenteral administration and does not contain a conventional antimicrobial preservative. The absence of preservatives supports single-dose hospital use but limits the commercial case for multidose presentations.

What is the role of lactose monohydrate?

Lactose monohydrate functions primarily as a lyophilization excipient. It contributes to the physical structure of the freeze-dried cake and provides formulation mass. In an injectable product, lactose selection requires control of moisture, crystallinity, particle characteristics, endotoxin burden, and compatibility with the active ingredient.

A reformulator should assess whether lactose affects:

• Cake appearance and mechanical integrity
• Residual moisture
• Reconstitution time
• Chemical degradation during storage
• Particulate formation
• Container-closure interaction
• Scale-up reproducibility

Alternative bulking systems could include mannitol, sucrose, trehalose, glycine, or combinations of crystalline and amorphous excipients. Each alternative changes the product's thermal behavior, collapse temperature, residual moisture profile, and reconstitution performance.

What excipient strategy is most suitable for tigecycline?

The preferred strategy depends on the commercial target.

Commercial target	Likely formulation strategy	Main value proposition
Standard generic	Lyophilized powder in vial	Lowest development and regulatory complexity
Premium hospital generic	Faster-reconstituting lyophilized cake	Reduced pharmacy labor and preparation time
Ready-to-use product	Liquid in vial or bag	Removes reconstitution step
Extended-stability product	Stabilized liquid or improved lyophilized formulation	Reduces wastage and supports pharmacy workflow
Pediatric or renal dosing product	Lower-strength vial or prefilled presentation	Reduces dosing manipulation
Automated pharmacy product	Bag, syringe, or barcode-ready unit dose	Supports compounding and administration systems
Emergency-use product	Premixed infusion bag	Enables rapid deployment

A standard lyophilized vial remains the lowest-risk approach. A differentiated product should focus on measurable operational performance rather than excipient novelty alone.

Can tigecycline be developed as a ready-to-use liquid?

A ready-to-use tigecycline formulation has commercial potential but presents higher technical risk than a conventional lyophilized product. Tigecycline is susceptible to degradation pathways that can affect potency, impurities, color, and solution stability. The liquid formulation must control pH, oxygen exposure, light exposure, temperature, container interaction, and adsorption.

Potential formulation levers include:

• pH optimization
• Buffer selection
• Chelating agents
• Antioxidants
• Nitrogen overlay or oxygen reduction
• Light-protective packaging
• Low-sorption container materials
• Cyclodextrin or other solubilizing systems
• Alternative concentration and dilution profiles

The formulation should avoid excipients that create unacceptable parenteral safety, osmolality, particulate, or compatibility risks. A liquid product also requires a robust extractables and leachables program, particularly for polymer containers, elastomeric closures, and administration sets.

What are the main risks for a liquid tigecycline formulation?

The primary risks are chemical instability and a shortened shelf life. The product must demonstrate stability at the labeled storage condition and, where claimed, after dilution and during administration.

Key studies include:

1. Forced degradation under heat, light, oxidation, hydrolysis, and pH stress.
2. Long-term, accelerated, and photostability studies.
3. In-use stability after vial access or bag spiking.
4. Compatibility with common infusion materials.
5. Assessment of sorption to tubing and containers.
6. Subvisible and visible particulate testing.
7. Sterility and container-closure integrity.
8. Compatibility with hospital pharmacy compounding systems.

A ready-to-use product is commercially attractive only if its stability profile reduces waste or labor enough to justify the higher manufacturing and regulatory burden.

What formulations are protected by tigecycline patents?

The original tigecycline product is now exposed to generic competition in the United States after expiration of the principal composition and product-related exclusivity periods. Current commercial value is more likely to arise from formulation, packaging, manufacturing, or device claims than from broad claims covering tigecycline itself.

Potential intellectual-property areas include:

• Stabilized aqueous tigecycline compositions
• Specific pH ranges
• Selected buffer or antioxidant systems
• Low-degradation liquid formulations
• Lyophilized cakes with defined excipient ratios
• Reconstitution systems
• Premixed infusion bags
• Container-closure combinations
• Manufacturing processes that reduce impurities
• Methods that extend in-use stability
• Pediatric or weight-based dosing presentations

Patent strength will depend on whether the claims cover a real technical distinction and whether the product can avoid the claims through changes in pH, excipient concentration, container type, or manufacturing conditions.

A formulation patent is stronger when it links a narrow composition to a measurable improvement, such as lower total impurities, improved reconstitution time, longer in-use stability, or reduced particulate formation. Broad claims that merely list conventional parenteral excipients face greater validity and design-around risk.

When does tigecycline lose exclusivity?

Tigecycline has already lost its core U.S. market exclusivity. Tygacil received FDA approval in 2005 for certain complicated skin and skin-structure infections and complicated intra-abdominal infections.[1] The product's principal composition and regulatory exclusivity periods have expired, allowing abbreviated new drug applications for tigecycline injection.

The current competitive issue is therefore not basic generic entry. It is whether a manufacturer can obtain a commercially meaningful position through:

• Lower manufacturing cost
• Reliable supply
• Improved vial utilization
• Reduced reconstitution time
• Premixed delivery
• Better stability after dilution
• Contract hospital agreements
• Alternative packaging
• Regional regulatory approvals

Patent status must be assessed by jurisdiction and product presentation. The existence of a tigecycline patent does not automatically block a conventional generic if the patent does not cover the proposed formulation or if the patent has expired.

What is the Orange Book status of tigecycline?

Tygacil is an FDA-approved listed drug, and generic tigecycline injections may rely on the abbreviated new drug application pathway when they meet the applicable requirements for strength, dosage form, route, quality, and bioequivalence or product sameness.

For injectable products, development emphasis typically falls on pharmaceutical equivalence, qualitative and quantitative formulation considerations, sterility, particulate control, container-closure integrity, stability, and manufacturing controls. The Orange Book should be reviewed for current reference-listed drug information, patents, exclusivity, and any listed use codes.[2]

A new liquid, premixed, or device-linked formulation may not fit cleanly within a conventional ANDA strategy. Depending on the changes, a 505(b)(2) application may offer a pathway to rely partly on FDA findings for the reference product while supporting new formulation, stability, or delivery claims with additional data.[3]

What generic entry risks exist for tigecycline?

The generic market has several entry risks despite expired core exclusivity.

Manufacturing and quality risks

Tigecycline requires control of degradation products, color, moisture, sterility, and reconstitution behavior. Lyophilization cycle development can become a major scale-up constraint. A small change in freezing, primary drying, or secondary drying conditions can alter cake structure and residual moisture.

Supply risks

Tigecycline is a hospital antibiotic. Buyers can place significant weight on supply continuity, shortage history, manufacturing-site redundancy, and approved alternate suppliers. A lower-priced product may lose contracts if it has unreliable availability.

Administration risks

The product requires reconstitution and dilution before infusion. Preparation errors can result from incorrect diluent volume, incomplete dissolution, wrong final concentration, or use outside the labeled stability period. A product that reduces these steps can compete on medication safety and pharmacy efficiency.

Clinical positioning risks

Tigecycline carries important safety and stewardship considerations, including an FDA boxed warning concerning increased all-cause mortality in a meta-analysis of clinical trials.[1] The product is not a broad first-line replacement for other hospital antibiotics. Commercial demand is concentrated in selected indications and clinical situations where its spectrum and route of administration are appropriate.

What commercial opportunities exist for tigecycline excipients?

Ready-to-use infusion bags

A ready-to-use bag could eliminate vial reconstitution, reduce pharmacy handling, and improve administration speed. The principal barriers are liquid stability, container compatibility, shelf life, shipping robustness, and the need to demonstrate an acceptable impurity profile.

Dual-chamber containers

A dual-chamber system could separate dry tigecycline from the diluent until administration. This approach may preserve stability while reducing manual preparation. It requires specialized packaging, device validation, human-factors assessment, and hospital workflow adoption.

Lower-strength presentations

A 10 mg or 25 mg presentation could support pediatric, low-weight, or dose-adjusted use while reducing the need to manipulate a 50 mg vial. The opportunity is limited by market size and the economics of an additional strength.

Pharmacy-ready syringes

A pharmacy-prepared or manufacturer-filled syringe could support emergency departments, intensive-care units, and automated dispensing environments. Sterility assurance, syringe compatibility, shelf life, and labeling requirements create substantial development obligations.

Reconstitution-enhanced vials

The most practical near-term opportunity may be a lyophilized vial with improved wetting, shorter reconstitution time, and a robust cake. This approach preserves the conventional product architecture while creating an operational advantage.

How does tigecycline compare with competing hospital antibiotics?

Attribute	Tigecycline	Other hospital injectable antibiotics
Primary formulation opportunity	Lyophilized vial, liquid, premix	Often premix, vial, or extended-infusion formats
Key excipient issue	Liquid instability and degradation control	Product-specific stability and compatibility
Preparation burden	Reconstitution and further dilution	Varies by drug and presentation
Commercial differentiation	Workflow, stability, supply, packaging	Dosing frequency, infusion duration, spectrum, cost
Clinical market	Selected complicated infections	Broad, often more competitive hospital categories
IP opportunity	Formulation and delivery claims	Formulation, dosing, infusion, and device claims

Tigecycline's commercial opportunity is narrower than that of high-volume broad-spectrum hospital antibiotics. A differentiated presentation must therefore produce a clear economic benefit for hospitals, group purchasing organizations, or specialty distributors.

Which companies are challenging or competing with Tygacil?

Competition comes primarily from generic injectable manufacturers and hospital suppliers rather than biosimilar developers. Tigecycline is a small-molecule antibiotic, so biosimilar risk does not apply. The relevant competitive set includes manufacturers with approved or developing tigecycline injection products, contract manufacturing capacity, and access to sterile injectable distribution.

Competitive assessment should examine:

• Current FDA-approved ANDA holders
• Product availability and back-order history
• Vial size and package configuration
• Contract manufacturing location
• DMF and API supply arrangements
• Approved shelf life
• Reconstitution instructions
• Hospital contract penetration
• International registrations
• Litigation or regulatory exclusivity affecting specific products

Because supplier participation can change, current FDA Drugs@FDA and Orange Book records should be used for a transaction-grade competitor map.[2][4]

Does tigecycline have biosimilar risk?

No. Tigecycline is a chemically synthesized small-molecule drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competition proceeds through generic or, for substantially modified products, potentially 505(b)(2) pathways.

The absence of biosimilar risk does not eliminate regulatory risk. A modified formulation may require additional clinical, pharmacokinetic, local tolerance, compatibility, or safety evidence depending on the extent of change and the proposed labeling.

What is the revenue exposure for a tigecycline reformulation?

Revenue exposure depends on hospital utilization, formulary positioning, price discount, and the ability to capture contracts. A conventional generic generally competes in a price-driven market. A premium presentation can support higher pricing only if it reduces measurable costs.

The most credible value metrics are:

• Minutes of pharmacy labor saved per dose
• Reduction in discarded vials
• Reduction in preparation errors
• Reduction in drug wastage after reconstitution
• Improved emergency department availability
• Reduced cold-chain or special handling costs
• Lower inventory complexity
• Improved fill-rate performance

A commercial model should compare the reformulated product's price premium with the hospital's avoided labor, waste, and medication-safety costs. Clinical differentiation is unlikely unless the formulation changes exposure, dosing, tolerability, or administration in a clinically meaningful way.

What patent litigation and settlement issues affect tigecycline?

The core tigecycline market is post-exclusivity, so litigation risk is more likely to concern later formulation or delivery patents than basic generic entry. Relevant issues include:

• Paragraph IV certifications against listed patents
• Patent validity and written-description challenges
• Infringement claims based on excipient ranges
• Settlement restrictions on launch timing
• ANDA litigation under the Hatch-Waxman Act
• Patent-term adjustment calculations
• Use-code scope for method-of-use patents

A company developing a liquid or premixed product should conduct a claim chart against active U.S. formulation and packaging patents before selecting excipients. Design-around options may include different stabilizer systems, concentration ranges, container materials, or manufacturing sequences.

What is the best commercial strategy for tigecycline?

The strongest near-term strategy is a differentiated sterile injectable product that retains the established lyophilized architecture while improving reconstitution speed, in-use handling, packaging, or supply reliability. A ready-to-use liquid has greater upside but also greater technical and regulatory risk.

A practical development sequence is:

1. Benchmark the reference product and major generics.
2. Identify the hospital workflow problem with the highest economic value.
3. Screen excipients against degradation and container-compatibility risks.
4. Develop a lyophilized and liquid concept in parallel.
5. Protect the selected composition, packaging, and process.
6. Select an ANDA or 505(b)(2) regulatory strategy.
7. Validate the commercial case with hospital pharmacy data.
8. Prioritize supply reliability and contract readiness.

Key Takeaways

• Tygacil uses a lyophilized tigecycline formulation containing lactose monohydrate and pH-adjusting agents.
• Core tigecycline exclusivity has expired, making standard generic entry possible.
• The main commercial opportunity is formulation and delivery differentiation, not new chemical-entity protection.
• A faster-reconstituting vial is lower risk than a ready-to-use liquid.
• A liquid, premixed, or dual-chamber product could reduce pharmacy labor but requires extensive stability and packaging work.
• Biosimilar competition is irrelevant because tigecycline is a small molecule.
• Formulation patents should focus on demonstrated stability, reconstitution, impurity, or packaging advantages.
• Hospital economics, supply reliability, and workflow improvement will determine commercial adoption.

FAQs

Can lactose-free excipients be used in a tigecycline injection?

Yes. Lactose can be replaced or supplemented with other parenteral bulking and stabilizing excipients, subject to compatibility, lyophilization performance, sterility, safety, and regulatory requirements.

Is a premixed tigecycline infusion commercially attractive?

It can be attractive if it delivers adequate shelf life, reduces preparation steps, and supports hospital purchasing economics. Liquid stability and container compatibility are the main development barriers.

Can tigecycline be supplied in a prefilled syringe?

Potentially, but the product would require validation of syringe materials, plunger interaction, extractables and leachables, sterility, particulate limits, stability, and labeling for the intended administration setting.

Would a new tigecycline formulation qualify for a 505(b)(2) application?

A materially modified formulation may qualify for a 505(b)(2) pathway if it relies partly on FDA findings for the reference product and provides appropriate new data supporting the formulation or delivery change.[3]

Are tigecycline formulation patents likely to block all generic products?

No. A formulation patent generally protects the claimed composition, process, package, or use. A competing manufacturer may avoid infringement through a different excipient system, concentration, container, or manufacturing process.

References

1. U.S. Food and Drug Administration. (2024). Tygacil (tigecycline) for injection prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2). Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.